C4 Therapeutics Inc
NASDAQ:CCCC 3:59:59 PM EDT
| Market Cap (Intraday) | 1.33B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $32.02 |
| 50-Day MA | $38.43 |
| 200-Day MA | N/A |
C4 Therapeutics Inc Stock, NASDAQ:CCCC
490 Arsenal Way, Suite 200, Watertown, Massachusetts 02472
United States of America
Phone: +1.617.231.0700
Number of Employees: 99
Description
C4 Therapeutics, Inc. provides new class of targeted protein degradation. It develops Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in October 2015 and is headquartered in Cambridge, MA.